Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Colistin + Meropenem (COL + MER) for the Treatment of Infections Caused by Metallo-β-Lactamase (MBL)-Producing Enterobacterales in Italy
Our analysis suggests that ATM-AVI is expected to be a cost-effective use of Italian healthcare resources for treating suspected metallo-β-lactamase-producing Enterobacterales, including complicated intra-abdominal infection and hospital-acquired pneumonia/ventilator-associated pneumonia.
Authors
- Michal Kantecki (ORCID: https://orcid.org/0009-0001-9222-5295)
- Roberto Di Virgilio
- Maria Alejandra Vidal Pereira (ORCID: https://orcid.org/0000-0002-8038-3026)
- Marco Falcone (ORCID: https://orcid.org/0000-0003-3813-8796)
- Maria Gheorghe (ORCID: https://orcid.org/0000-0002-4128-6063)
- Fionn Woodcock
- Xue Bao (ORCID: https://orcid.org/0000-0002-5129-0728)
Institutions
- University of Pisa (IT)
- Pfizer (United States) (US)
- Petroleum & Gas University of Ploieşti (RO)
- Office Of Health Economics (GB)
- Pfizer (France) (FR)
- Pfizer (Italy) (IT)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1007/s40273-025-01528-6
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00